31 results about "P2Y12" patented technology

A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb / IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb / IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin E1 (PGE1), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation.

The present invention relates to certain novel pyridin compounds of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.

The present invention relates to certain novel pyridin compounds of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-thrombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.

The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.

The invention relates to an application of a receptor p2y12 of ADP (adenosine diphosphate) in angiogenesis. Concretely, the receptor p2y12 of ADP is specifically expressed in vascular endothelial cells, and a specific inhibitor of p2y12 is used for inhibiting p2y12 expression and preventing blood vessels among somites from generating growth defects; the ligand ADP of p2y12 is also involved in angiogenesis, and a high-selectivity antagonist is utilized to block ADP to activate p2y12 to have an exception which is the same as the above exception; an ADP-p2y12 signal is involved in the angiogenesis process in modes of migrating and proliferating tip cells, namely regulating tip cell behaviors; otherwise, p2y12 overexpression can promote the obtaining of tip cell, namely the number of endothelial cells with excessive migration and endothelial cells involved in angiogenesis among somites is obviously increased; in addition, the ADP-p2y12 signal inhibits a notch pathway so as to regulate angiogenesis in vivo. The application of the receptor p2y12 of ADPin angiogenesis provides a new target for related diseases of intervention in angiogenesis.